Laura M. Heiser - Publications

Affiliations: 
Lawrence Berkeley National Laboratory, Berkeley, CA, USA 
Area:
spatial cognition

27/103 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Brown A, Patel S, Ward C, Lorenz A, Ortiz M, DuRoss A, Wieghardt F, Esch A, Otten EG, Heiser LM, Korolchuk VI, Sun C, Sarkar S, Sahay G. PEG-lipid micelles enable cholesterol efflux in Niemann-Pick Type C1 disease-based lysosomal storage disorder. Scientific Reports. 6: 31750. PMID 27572704 DOI: 10.1038/Srep31750  0.84
2016 Hu Z, Mao JH, Curtis C, Huang G, Gu S, Heiser L, Lenburg ME, Korkola JE, Bayani N, Samarajiwa S, Seoane JA, A Dane M, Esch A, Feiler HS, Wang NJ, et al. Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Research : Bcr. 18: 70. PMID 27368372 DOI: 10.1186/S13058-016-0728-Y  0.84
2016 Hill SM, Heiser LM, Cokelaer T, Unger M, Nesser NK, Carlin DE, Zhang Y, Sokolov A, Paull EO, Wong CK, Graim K, Bivol A, Wang H, Zhu F, Afsari B, et al. Inferring causal molecular networks: empirical assessment through a community-based effort. Nature Methods. PMID 26901648 DOI: 10.1038/Nmeth.3773  0.84
2015 Laderas TG, Heiser LM, Sönmez K. A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity. Frontiers in Genetics. 6: 341. PMID 26779250 DOI: 10.3389/fgene.2015.00341  0.84
2015 Lue HW, Cole B, Rao SA, Podalak J, Van Gaest A, King C, Eide CA, Wilmot B, Xue C, Spellman PT, Heiser LM, Tyner JW, Thomas GV. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma. Oncotarget. PMID 26625308 DOI: 10.18632/Oncotarget.5971  0.84
2015 Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-derived Cell Lines as Molecular Models of Cancer Pharmacogenomics. Molecular Cancer Research : McR. PMID 26248648 DOI: 10.1158/1541-7786.Mcr-15-0189  0.84
2015 Korkola JE, Collisson EA, Heiser L, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, et al. Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. Plos One. 10: e0133219. PMID 26181325 DOI: 10.1371/Journal.Pone.0133219  0.84
2015 Giuliano M, Hu H, Wang YC, Fu X, Nardone A, Herrera S, Mao S, Contreras A, Gutierrez C, Wang T, Hilsenbeck SG, De Angelis C, Wang NJ, Heiser LM, Gray JW, et al. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26015514 DOI: 10.1158/1078-0432.CCR-14-2728  0.84
2014 Bansal M, Yang J, Karan C, Menden MP, Costello JC, Tang H, Xiao G, Li Y, Allen J, Zhong R, Chen B, Kim M, Wang T, Heiser LM, Realubit R, et al. A community computational challenge to predict the activity of pairs of compounds. Nature Biotechnology. 32: 1213-22. PMID 25419740 DOI: 10.1038/Nbt.3052  0.84
2014 Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, ... Heiser LM, et al. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Research : Bcr. 16: 430. PMID 25212826 DOI: 10.1186/S13058-014-0430-X  0.84
2014 Costello JC, Heiser LM, Georgii E, Gönen M, Menden MP, Wang NJ, Bansal M, Ammad-ud-din M, Hintsanen P, Khan SA, Mpindi JP, Kallioniemi O, Honkela A, Aittokallio T, Wennerberg K, et al. A community effort to assess and improve drug sensitivity prediction algorithms. Nature Biotechnology. 32: 1202-12. PMID 24880487 DOI: 10.1038/nbt.2877  0.84
2013 Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, et al. Modeling precision treatment of breast cancer. Genome Biology. 14: R110. PMID 24176112 DOI: 10.1186/Gb-2013-14-10-R110  0.84
2013 Griffith OL, Pepin F, Enache OM, Heiser LM, Collisson EA, Spellman PT, Gray JW. A robust prognostic signature for hormone-positive node-negative breast cancer. Genome Medicine. 5: 92. PMID 24112773 DOI: 10.1186/Gm496  0.84
2013 Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW, Sorger PK. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nature Chemical Biology. 9: 708-14. PMID 24013279 DOI: 10.1038/nchembio.1337  0.84
2012 Ordinario E, Han HJ, Furuta S, Heiser LM, Jakkula LR, Rodier F, Spellman PT, Campisi J, Gray JW, Bissell MJ, Kohwi Y, Kohwi-Shigematsu T. ATM suppresses SATB1-induced malignant progression in breast epithelial cells. Plos One. 7: e51786. PMID 23251624 DOI: 10.1371/Journal.Pone.0051786  0.84
2012 Hill SM, Lu Y, Molina J, Heiser LM, Spellman PT, Speed TP, Gray JW, Mills GB, Mukherjee S. Bayesian inference of signaling network topology in a cancer cell line. Bioinformatics (Oxford, England). 28: 2804-10. PMID 22923301 DOI: 10.1093/Bioinformatics/Bts514  0.84
2012 Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, Spellman PT, Phillips WA, Gray JW, McMahon M. A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discovery. 2: 685-93. PMID 22628411 DOI: 10.1158/2159-8290.Cd-11-0347  0.84
2012 Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 109: 2724-9. PMID 22003129 DOI: 10.1073/Pnas.1018854108  0.84
2009 Kuo WL, Das D, Ziyad S, Bhattacharya S, Gibb WJ, Heiser LM, Sadanandam A, Fontenay GV, Hu Z, Wang NJ, Bayani N, Feiler HS, Neve RM, Wyrobek AJ, Spellman PT, et al. A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. Bmc Medicine. 7: 77. PMID 20003408 DOI: 10.1186/1741-7015-7-77  0.84
2009 Heiser LM, Wang NJ, Talcott CL, Laderoute KR, Knapp M, Guan Y, Hu Z, Ziyad S, Weber BL, Laquerre S, Jackson JR, Wooster RF, Kuo WL, Gray JW, Spellman PT. Integrated analysis of breast cancer cell lines reveals unique signaling pathways. Genome Biology. 10: R31. PMID 19317917 DOI: 10.1186/Gb-2009-10-3-R31  0.84
2007 Wang Y, Moorhead M, Karlin-Neumann G, Wang NJ, Ireland J, Lin S, Chen C, Heiser LM, Chin K, Esserman L, Gray JW, Spellman PT, Faham M. Analysis of molecular inversion probe performance for allele copy number determination. Genome Biology. 8: R246. PMID 18028543 DOI: 10.1186/Gb-2007-8-11-R246  0.84
2007 Berman RA, Heiser LM, Dunn CA, Saunders RC, Colby CL. Dynamic circuitry for updating spatial representations. III. From neurons to behavior. Journal of Neurophysiology. 98: 105-21. PMID 17493922 DOI: 10.1152/Jn.00330.2007  0.84
2007 Parvin B, Ghosh N, Heiser L, Knapp M, Talcott C, Laderoute K, Gray J, Spellman P. Spectral decomposition of signaling networks 2007 Ieee Symposium On Computational Intelligence and Bioinformatics and Computational Biology, Cibcb 2007. 76-81.  0.84
2006 Heiser LM, Colby CL. Spatial updating in area LIP is independent of saccade direction. Journal of Neurophysiology. 95: 2751-67. PMID 16291805 DOI: 10.1152/jn.00054.2005  0.84
2005 Colby CL, Berman RA, Heiser LM, Saunders RC. Corollary discharge and spatial updating: when the brain is split, is space still unified? Progress in Brain Research. 149: 187-205. PMID 16226585 DOI: 10.1016/S0079-6123(05)49014-7  0.84
2005 Berman RA, Heiser LM, Saunders RC, Colby CL. Dynamic circuitry for updating spatial representations. I. Behavioral evidence for interhemispheric transfer in the split-brain macaque. Journal of Neurophysiology. 94: 3228-48. PMID 15888534 DOI: 10.1152/jn.00028.2005  0.84
2005 Heiser LM, Berman RA, Saunders RC, Colby CL. Dynamic circuitry for updating spatial representations. II. Physiological evidence for interhemispheric transfer in area LIP of the split-brain macaque. Journal of Neurophysiology. 94: 3249-58. PMID 15888533 DOI: 10.1152/jn.00029.2005  0.84
Low-probability matches
2015 Hu H, Simon L, Qin L, Nardone A, Shaw C, Chamness G, Heiser L, Wang N, Gray JW, Osborne CK, Schiff R. Abstract 721: Mevalonate pathway mediates acquired anti-HER2 treatment resistance in HER2+ breast cancer Cancer Research. 75: 721-721. DOI: 10.1158/1538-7445.Am2015-721  0.12
2020 Kimmel GJ, Dane M, Heiser LM, Altrock PM, Andor N. Integrating mathematical modeling with high throughput imaging explains how polyploid populations behave in nutrient-sparse environments. Cancer Research. PMID 32938640 DOI: 10.1158/0008-5472.CAN-20-1231  0.08
2019 Coleman DJ, Gao L, King CJ, Schwartzman J, Urrutia J, Sehrawat A, Tayou J, Balter A, Burchard J, Chiotti KE, Derrick DS, Sun D, Xia Z, Heiser LM, Alumkal JJ. BET bromodomain inhibition blocks the function of a critical AR-independent master regulator network in lethal prostate cancer. Oncogene. PMID 30996246 DOI: 10.1038/s41388-019-0815-5  0.08
2019 Coleman DJ, Gao L, Schwartzman J, Korkola JE, Sampson D, Derrick DS, Urrutia J, Balter A, Burchard J, King CJ, Chiotti KE, Heiser LM, Alumkal JJ. Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer. Scientific Reports. 9: 3823. PMID 30846826 DOI: 10.1038/s41598-019-40518-5  0.08
2020 Smith R, Devlin K, Liu M, Liby T, Kilburn D, Bucher E, Sudar D, Thibault G, Dane M, Gray J, Heiser L, Korkola JE. Abstract 1870: The impact of the microenvironment on heterogeneity and trametinib response in HCC1143 triple negative breast cancer cells Cancer Research. 80: 1870-1870. DOI: 10.1158/1538-7445.Am2020-1870  0.04
2019 Sethunath V, Hu H, De Angelis C, Veeraraghavan J, Qin L, Wang N, Simon LM, Wang T, Fu X, Nardone A, Pereira R, Nanda S, Griffith OL, Tsimelzon A, Shaw C, ... ... Heiser LM, et al. . Molecular Cancer Research : McR. PMID 31420371 DOI: 10.1158/1541-7786.Mcr-19-0756  0.04
2019 Niepel M, Hafner M, Mills CE, Subramanian K, Williams EH, Chung M, Gaudio B, Barrette AM, Stern AD, Hu B, Korkola JE, Gray JW, Birtwistle MR, Heiser LM, et al. A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines. Cell Systems. PMID 31302153 DOI: 10.1016/J.Cels.2019.06.005  0.04
2018 Watson SS, Dane M, Chin K, Tatarova Z, Liu M, Liby T, Thompson W, Smith R, Nederlof M, Bucher E, Kilburn D, Whitman M, Sudar D, Mills GB, Heiser LM, et al. Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes. Cell Systems. PMID 29550255 DOI: 10.1016/j.cels.2018.02.001  0.04
2017 Korkola JE, Collisson EA, Heiser LM, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, et al. Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. Plos One. 12: e0186551. PMID 29020035 DOI: 10.1371/Journal.Pone.0186551  0.04
2017 Korkola J, Liu M, Smith R, Liby T, Heiser L, Gray J. Abstract P6-08-01: A directed siRNA screen identifies INHBA as a major regulator of tumor aggressiveness in basal HER2 breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-08-01  0.04
2016 Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R, Thomas GV, Beer TM, Gleave M, Korkola JE, Gao L, ... Heiser LM, et al. Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget. PMID 27276681 DOI: 10.18632/oncotarget.9816  0.04
2015 Woodward J, King C, Coleman D, Lisac R, Schwartzman J, Wang N, Gleave M, Gray J, Thomas G, Beer TM, Hook KV, Baertsch R, Goldstein T, Stuart J, Gao L, ... ... Heiser L, et al. Abstract 731: Integrative genomic analysis to identify emergent enzalutamide resistance mechanisms in castration-resistant prostate cancer Cancer Research. 75: 731-731. DOI: 10.1158/1538-7445.Am2015-731  0.04
2015 Coleman D, Hook KV, Lisac R, King C, Wang N, Schwartzman J, Gleave M, Gao L, Urrutia J, Heiser L, Alumkal JJ. Abstract 3592: Androgens interfere with enzalutamide agonism of mutant F876L androgen receptor Cancer Research. 75: 3592-3592. DOI: 10.1158/1538-7445.Am2015-3592  0.04
2013 Bastek JA, Hirshberg A, Chandrasekaran S, Owen CM, Heiser LM, Araujo BA, McShea MA, Ryan ME, Elovitz MA. Biomarkers and cervical length to predict spontaneous preterm birth in asymptomatic high-risk women. Obstetrics and Gynecology. 122: 283-9. PMID 23969796 DOI: 10.1097/AOG.0b013e31829ab714  0.04
2013 Heiser LM, Shaw CA, Wang NJ, Grasso C, Anur P, Ng S, Goldstein T, Spellman PT, Stuart J, Osborne K, Gray J, Schiff R. Abstract 5238: Acquired therapeutic resistance is mediated by deregulation of multiple pathways. Cancer Research. 73: 5238-5238. DOI: 10.1158/1538-7445.Am2013-5238  0.04
2011 Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, Dhir R, Disaia P, Gabra H, Glenn P, Godwin AK, Gross J, Hartmann L, Huang M, Huntsman DG, et al. Integrated genomic analyses of ovarian carcinoma Nature. 474: 609-615. PMID 21720365 DOI: 10.1038/Nature10166  0.04
2021 Lue HW, Derrick DS, Rao S, Van Gaest A, Cheng L, Podolak J, Lawson S, Xue C, Garg D, White R, Ryan CW, Drake JM, Ritz A, Heiser LM, Thomas GV. Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma. Cell Reports. Medicine. 2: 100267. PMID 34095877 DOI: 10.1016/j.xcrm.2021.100267  0.01
2021 Li A, Keck JM, Parmar S, Patterson J, Labrie M, Creason AL, Johnson BE, Downey M, Thomas G, Beadling C, Heiser LM, Kolodzie A, Guimaraes AR, Corless CL, Gray JW, et al. Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics. Npj Precision Oncology. 5: 28. PMID 33772089 DOI: 10.1038/s41698-021-00165-4  0.01
2020 Kersch CN, Claunch CJ, Ambady P, Bucher E, Schwartz DL, Barajas RF, Iliff JJ, Risom T, Heiser L, Muldoon LL, Korkola JE, Gray JW, Neuwelt EA. Transcriptional signatures in histologic structures within glioblastoma tumors may predict personalized drug sensitivity and survival. Neuro-Oncology Advances. 2: vdaa093. PMID 32904984 DOI: 10.1093/noajnl/vdaa093  0.01
2020 Goecks J, Jalili V, Heiser LM, Gray JW. How Machine Learning Will Transform Biomedicine. Cell. 181: 92-101. PMID 32243801 DOI: 10.1016/J.Cell.2020.03.022  0.01
2020 Hunt GJ, Dane MA, Korkola JE, Heiser LM, Gagnon-Bartsch JA. Automatic Transformation and Integration to Improve Visualization and Discovery of Latent Effects in Imaging Data Journal of Computational and Graphical Statistics. 1-13. DOI: 10.1080/10618600.2020.1741379  0.01
2019 Meyer AS, Heiser LM. Systems biology approaches to measure and model phenotypic heterogeneity in cancer. Current Opinion in Systems Biology. 17: 35-40. PMID 32864511 DOI: 10.1016/j.coisb.2019.09.002  0.01
2019 Gross SM, Dane MA, Bucher E, Heiser LM. Individual Cells Can Resolve Variations in Stimulus Intensity along the IGF-PI3K-AKT Signaling Axis. Cell Systems. PMID 31838146 DOI: 10.1016/J.Cels.2019.11.005  0.01
2019 Bucher E, Claunch CJ, Hee D, Smith RL, Devlin K, Thompson W, Korkola JE, Heiser LM. Annot: a Django-based sample, reagent, and experiment metadata tracking system. Bmc Bioinformatics. 20: 542. PMID 31675914 DOI: 10.1186/s12859-019-3147-0  0.01
2019 Brown AG, Maubert ME, Anton L, Heiser LM, Elovitz MA. The tracking of lipopolysaccharide through the feto-maternal compartment and the involvement of maternal TLR4 in inflammation-induced fetal brain injury. American Journal of Reproductive Immunology (New York, N.Y. : 1989). PMID 31495009 DOI: 10.1111/aji.13189  0.01
2019 Schau GF, Thibault G, Dane MA, Gray JW, Heiser LM, Chang YH. Variational Autoencoding Tissue Response to Microenvironment Perturbation. Proceedings of Spie--the International Society For Optical Engineering. 10949. PMID 31379401 DOI: 10.1117/12.2512660  0.01
2019 Smith R, Devlin K, Kilburn D, Gross S, Sudar D, Bucher E, Nederlof M, Dane M, Gray JW, Heiser L, Korkola JE. Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer. Journal of Visualized Experiments : Jove. PMID 31180341 DOI: 10.3791/58957  0.01
2019 Heiser LM, Mills GB, Gray JW. Therapeutic Clues from an Integrated Omic Assessment of East Asian Triple Negative Breast Cancers. Cancer Cell. 35: 341-343. PMID 30889376 DOI: 10.1016/j.ccell.2019.02.012  0.01
2019 Keck JM, Parmar S, Kong B, Mitri Z, Corless C, Kolodzie A, Creason A, Goecks J, Leyshock P, Siex K, Johnson BE, Patterson J, Heiser L, Olson A, Viehdorfer M, et al. Abstract 4929: Leveraging multi-omics tumor boards for precision medicine in the OHSU SMMART Treatments Program Cancer Research. 79: 4929-4929. DOI: 10.1158/1538-7445.Sabcs18-4929  0.01
2019 White BS, Gentles AJ, Reyniès Ad, Newman AM, Lamb A, Heiser L, Waterfall JJ, Yu T, Guinney J. Abstract 1690: A tumor deconvolution DREAM Challenge: Inferring immune infiltration from bulk gene expression data Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-1690  0.01
2019 Kersch C, Claunch C, Ambady P, Bucher E, Schwartz D, Barajas R, Iliff J, Heiser L, Muldoon L, Neuwelt E. Path-63. Transcriptional Signatures In Histologic Structures Within Glioblastoma Tumors May Predict Personalized Treatment Sensitivity And Survival Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.658  0.01
2018 Anton L, Sierra LJ, DeVine A, Barila G, Heiser L, Brown AG, Elovitz MA. Common Cervicovaginal Microbial Supernatants Alter Cervical Epithelial Function: Mechanisms by Which Contributes to Cervical Health. Frontiers in Microbiology. 9: 2181. PMID 30349508 DOI: 10.3389/fmicb.2018.02181  0.01
2018 Sehrawat A, Gao L, Wang Y, Bankhead A, McWeeney SK, King CJ, Schwartzman J, Urrutia J, Bisson WH, Coleman DJ, Joshi SK, Kim DH, Sampson DA, Weinmann S, Kallakury BVS, ... ... Heiser LM, et al. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proceedings of the National Academy of Sciences of the United States of America. PMID 29581250 DOI: 10.1073/Pnas.1719168115  0.01
2018 Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, ... ... Heiser LM, et al. Publisher Correction: Combating subclonal evolution of resistant cancer phenotypes. Nature Communications. 9: 572. PMID 29402882 DOI: 10.1038/S41467-017-02383-6  0.01
2018 Keenan AB, Jenkins SL, Jagodnik KM, Koplev S, He E, Torre D, Wang Z, Dohlman AB, Silverstein MC, Lachmann A, Kuleshov MV, Ma'ayan A, Stathias V, Terryn R, Cooper D, ... ... Heiser LM, et al. The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations. Cell Systems. 6: 13-24. PMID 29199020 DOI: 10.1016/J.Cels.2017.11.001  0.01
2018 Johnson B, Keck J, Morris M, Siex K, Kolodzie A, Parmar S, Riesterer J, Chin K, Gibbs S, Heiser L, Spellman P, Ellrott K, Babur O, Demir E, Margolin A, et al. Abstract 3296: SMMART: Serial measurements of molecular and architectural responses to therapy Cancer Research. 78: 3296-3296. DOI: 10.1158/1538-7445.Am2018-3296  0.01
2018 Downes KL, Heiser L, Elovitz MA. 702: Longitudinal changes in cervicovaginal antimicrobial peptides during pregnancy and association with spontaneous preterm birth American Journal of Obstetrics and Gynecology. 218: S422. DOI: 10.1016/j.ajog.2017.11.232  0.01
2017 King CJ, Woodward J, Schwartzman J, Coleman DJ, Lisac R, Wang NJ, Van Hook K, Gao L, Urrutia J, Dane MA, Heiser LM, Alumkal JJ. Integrative molecular network analysis identifies emergent enzalutamide resistance mechanisms in prostate cancer. Oncotarget. 8: 111084-111095. PMID 29340039 DOI: 10.18632/oncotarget.22560  0.01
2017 Farrell AS, Joly MM, Allen-Petersen BL, Worth PJ, Lanciault C, Sauer D, Link J, Pelz C, Heiser LM, Morton JP, Muthalagu N, Hoffman MT, Manning SL, Pratt ED, Kendsersky ND, et al. MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance. Nature Communications. 8: 1728. PMID 29170413 DOI: 10.1038/S41467-017-01967-6  0.01
2017 Hafner M, Heiser LM, Williams EH, Niepel M, Wang NJ, Korkola JE, Gray JW, Sorger PK. Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics. Scientific Data. 4: 170166. PMID 29112189 DOI: 10.1038/sdata.2017.166  0.01
2017 Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, ... ... Heiser LM, et al. Combating subclonal evolution of resistant cancer phenotypes. Nature Communications. 8: 1231. PMID 29093439 DOI: 10.1038/S41467-017-01174-3  0.01
2017 Hassan S, Esch A, Liby T, Gray JW, Heiser LM. Pathway-enriched gene signature associated with 53BP1 response to PARP inhibition in triple-negative breast cancer. Molecular Cancer Therapeutics. PMID 28958991 DOI: 10.1158/1535-7163.Mct-17-0170  0.01
2017 Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang NJ, Ng CKY, Chen E, Renwick A, Wang T, Nanda S, et al. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28487443 DOI: 10.1158/1078-0432.Ccr-16-2191  0.01
2017 Rahman M, MacNeil SM, Jenkins DF, Shrestha G, Wyatt SR, McQuerry JA, Piccolo SR, Heiser LM, Gray JW, Johnson WE, Bild AH. Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes. Genome Medicine. 9: 40. PMID 28446242 DOI: 10.1186/s13073-017-0429-x  0.01
2017 Hu Z, Mao JH, Curtis C, Huang G, Gu S, Heiser L, Lenburg ME, Korkola JE, Bayani N, Samarajiwa S, Seoane JA, Dane MA, Esch A, Feiler HS, Wang NJ, et al. Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Research : Bcr. 19: 17. PMID 28183333 DOI: 10.1186/S13058-017-0809-6  0.01
2017 Hassan S, Esch A, Heiser LM, Gray JW. Abstract B24: Genomic prediction of response to PARP inhibition in breast cancer Molecular Cancer Research. 15. DOI: 10.1158/1557-3125.Dnarepair16-B24  0.01
2017 Korkola J, Watson S, Smith R, Thompson W, Dame M, Liby T, Bucher E, Sudar D, Nederlof M, Heiser L, Gray J. Abstract PD5-01: Microenvironment microarrays show that microenvironment mediated resistance mechanisms to lapatinib differ between basal and luminal HER2+ cells Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Pd5-01  0.01
2017 Nikolova OH, Heiser L, Margolin AA. Abstract 5548: Genomic signatures for tumor-to-treatment stratification in pancreatic cancer Cancer Research. 77: 5548-5548. DOI: 10.1158/1538-7445.Am2017-5548  0.01
2017 Sehrawat A, Gao L, Tayou J, Bankhead A, Heiser LM, King CJ, Wang Y, Schwartzman J, Urrutia J, Coleman DJ, Weinmann S, Kallakury BV, Berry DL, Haque R, Eeden SKVD, et al. Abstract 2406: LSD1 promotes castration-resistant prostate cancer cell survival independently of the androgen receptor and of histone demethylation Cancer Research. 77: 2406-2406. DOI: 10.1158/1538-7445.Am2017-2406  0.01
2017 Cheng JB, Harirchian P, Greer J, Parsons M, Heiser LM, Mauro T, Cho RJ. Image-based transcription factor siRNA screen reveals novel regulators of epidermal differentiation Journal of Dermatological Science. 86: e41. DOI: 10.1016/J.Jdermsci.2017.02.120  0.01
2016 Hill SM, Nesser NK, Johnson-Camacho K, Jeffress M, Johnson A, Boniface C, Spencer SE, Lu Y, Heiser LM, Lawrence Y, Pande NT, Korkola JE, Gray JW, Mills GB, Mukherjee S, et al. Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling. Cell Systems. PMID 28017544 DOI: 10.1016/J.Cels.2016.11.013  0.01
2016 Fu X, Jeselsohn R, Pereira R, Hollingsworth EF, Creighton CJ, Li F, Shea M, Nardone A, De Angelis C, Heiser LM, Anur P, Wang N, Grasso CS, Spellman PT, Griffith OL, et al. FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 113: E6600-E6609. PMID 27791031 DOI: 10.1073/Pnas.1612835113  0.01
2016 Coleman DJ, Van Hook K, King CJ, Schwartzman J, Lisac R, Urrutia J, Sehrawat A, Woodward J, Wang NJ, Gulati R, Thomas GV, Beer TM, Gleave ME, Korkola JE, Gao L, ... Heiser LM, et al. Androgen content and BET bromodomain proteins influence enzalutamide agonism of mutant F876L androgen receptor. Journal of Clinical Oncology. 34: e16538-e16538. DOI: 10.1200/jco.2016.34.15_suppl.e16538  0.01
2016 Gao L, Coleman DJ, King CJ, Schwartzman J, Wang N, Esch A, Urrutia J, Sehrawat A, Heiser LM, Alumkal JJ. Abstract 4700: BET bromodomain inhibition is a promising treatment strategy for distinct subsets of lethal castration-resistant prostate cancer Cancer Research. 76: 4700-4700. DOI: 10.1158/1538-7445.Am2016-4700  0.01
2015 Esch A, Heiser L, Gray JW. Biological indicators of response and resistance to PARP inhibition in BRCA wild-type breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 125. PMID 28147797 DOI: 10.1200/Jco.2015.33.28_Suppl.125  0.01
2015 Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, et al. Erratum to: Modeling precision treatment of breast cancer. Genome Biology. 16: 95. PMID 25962591 DOI: 10.1186/S13059-015-0658-5  0.01
2015 Korkola JE, Liu M, Liby T, Heiser L, Feiler H, Gray JW. Abstract S6-07: Detrimental effects of sequential compared to concurrent treatment of pertuzumab plus T-DM1 in HER2+ breast cancer cell lines Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S6-07  0.01
2015 Fu X, Jeselsohn R, Hollingsworth EF, Lopez-Terrada D, Creighton CJ, Nardone A, Shea M, Heiser LM, Anur P, Wang N, Grasso C, Spellman P, Gutierrez C, Rimawi MF, Hilsenbeck SG, et al. Abstract PD6-2: FoxA1 gene amplification in ER+ breast cancer mediates endocrine resistance by increasing IL-8 Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd6-2  0.01
2015 Xu X, Nardone A, Hu H, Qin L, Nanda S, Heiser LM, Wang N, Covington KR, Chen ES, Renwick A, Wang T, Angelis CD, Contreras A, Gutierrez C, Fuqua SA, et al. Abstract P5-05-03: Clonal evolution of the HER2 L755S mutation leads to acquired HER-targeted therapy resistance that can be reversed by the irreversible HER1/2 inhibitor afatinib Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-05-03  0.01
2015 Hu H, Simon LM, Nardone A, Shaw CA, Chamness GC, Heiser LM, Wang N, Osborne CK, Schiff R. Abstract P5-05-01: Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-05-01  0.01
2015 Wolf DM, Yau C, Sanil A, Daemen A, Heiser L, Gray J, Brown-Swigart L, Flynn S, Hirst G, Investigators IT, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, et al. Abstract P3-06-05: Evaluation of anin vitroderived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL: Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-06-05  0.01
2015 Qin L, Hahn MB, Fu X, Shea MJ, Giuliano M, Nanda S, Xu X, Hu H, Jung SY, Heiser LM, Wang N, Gray JW, Hilsenbeck SG, Creighton C, Shaw CA, et al. Abstract P3-05-13: Overexpression of insulin receptor substrate 4 can mediate acquired resistance to lapatinib-containing regimens in HER2+ breast cancer cells Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P3-05-13  0.01
2015 Xu X, Nardone A, Hu H, Qin L, Nanda S, Heiser L, Wang N, Covington K, Chen E, Renwick A, Mitchell T, Shea M, Wang T, Angelis CD, Contreras A, et al. Abstract 737: Clonal evolution of the HER2 L755S mutation as a mechanism of acquired HER-targeted therapy resistance Cancer Research. 75: 737-737. DOI: 10.1158/1538-7445.Am2015-737  0.01
2014 Elovitz MA, Brown AG, Anton L, Gilstrop M, Heiser L, Bastek J. Distinct cervical microRNA profiles are present in women destined to have a preterm birth. American Journal of Obstetrics and Gynecology. 210: 221.e1-11. PMID 24565431 DOI: 10.1016/j.ajog.2013.12.043  0.01
2014 Alumkal JJ, Heiser L, Beer TM, Small EJ, Baertsch R, Stuart J, King C, Korkola J, Cetnar J, Graff JN, Thomas G, Ryan CW, Toschi A, Youngren J, Tucker E, et al. Identifying enzalutamide resistance mechanisms in men with castration-resistant prostate cancer. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps5104  0.01
2014 Risom T, Rantala J, Langer E, Wang N, Heiser L, Troxell M, Gray J, Sears R. Abstract LB-222: Differentiation state heterogeneity in breast cancer and its role in therapeutic response Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-222  0.01
2014 Fallahi-Sichani M, Honarnejad S, Heiser LM, Gray JW, Sorger PK. Abstract 5502: Metrics other than potency reveal systematic variation in responses to cancer drugs Cancer Research. 74: 5502-5502. DOI: 10.1158/1538-7445.Am2014-5502  0.01
2014 Brown A, Anton L, Nold C, Heiser L, Elovitz M. 437: Targeting TLR-4 prevents an immune response in the placenta and fetus after exposure to intrauterine inflammation American Journal of Obstetrics and Gynecology. 210: S221-S222. DOI: 10.1016/j.ajog.2013.10.470  0.01
2013 Korkola JE, Rantala J, Bayani N, Heiser L, Wang N, Griffith O, Gray J. Abstract 2387: Activation of Inhibin A signaling is associated with a basal-like HER2 subtype and resistance to lapatinib in breast cancer cell lines. Cancer Research. 73: 2387-2387. DOI: 10.1158/1538-7445.Am2013-2387  0.01
2012 Heiser L, Neuman K, Altman K, Brandt K, Painter J. Raisins and Dental Caries Education Material Journal of the Academy of Nutrition and Dietetics. 112: A51. DOI: 10.1016/j.jand.2012.06.182  0.01
2011 Listerman I, Gazzaniga FS, Heiser LM, Lukas JJ, Goldstein T, Haussler D, Gray JW, Blackburn EH. Abstract A58: Wnt signaling pathway components are associated with telomerase activity in breast cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Fbcr11-A58  0.01
2011 Korkola J, Bayani N, Cooper B, Heiser LM, Spellman PT, Feiler HS, Wooster R, Gray JW. Abstract 639: Inhibition of HER2 signaling using targeted therapeutics in breast cancer cell lines Cancer Research. 71: 639-639. DOI: 10.1158/1538-7445.Am2011-639  0.01
2011 Ng S, Vaske C, Benz S, Durbin J, Szeto C, Heiser L, Wang N, Korkola J, Bayani N, Spellman P, Gray JW, Haussler D, Stuart J. Abstract 49: Constructing pathway based predictors of cancer clinical outcome Cancer Research. 71: 49-49. DOI: 10.1158/1538-7445.Am2011-49  0.01
2010 Gibb WJ, Collisson E, Korkola J, Heiser L, Sadanandam A, Kuo W, Hu Z, Mao J, Wang N, Bayani N, Billig J, Ziyad S, Lewis S, Feiler H, Jakkula L, et al. Abstract 1979: Algebraic factorization of gene expression profiles reveals subtype-specific drug sensitivities among 54 breast cancer cell lines Cancer Research. 70: 1979-1979. DOI: 10.1158/1538-7445.Am10-1979  0.01
2009 Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Research. 69: 565-72. PMID 19147570 DOI: 10.1158/0008-5472.Can-08-3389  0.01
2004 Berman RA, Heiser LM, Saunders RC, Colby CL. Visuospatial updating in the split-brain Journal of Vision. 4: 887-887. DOI: 10.1167/4.8.887  0.01
Hide low-probability matches.